Tenderwize
Wróć do wyszukiwania

Open-house rebate agreement for Solifenacin/Tamsulosin

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Feb 29, 2028 · 551 days left·Open·Supplies·Framework
Zarejestruj się, aby zapisaćOpen documents
Oryginalny tytuł ogłoszenia

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Solifenacin/Tamsulosin (ATC-Code nach WHO: G04CA53)

46/100

Ocena szansy

Needs reviewMedium complexity
SuppliesFrameworkOpen
Skąd ta ocena?

Szansa

46 / 100

Złożoność

58 / 100

Czynniki ryzyka

The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...

Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.

Głęboka analiza portfolio

Głęboka analiza dopasowania firmy

Wykorzystuje:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Przegląd

Moderate opportunity

Kluczowe fakty

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Feb 2028
  • Conclusion of non-exclusive rebate agreements for pharmaceutical products containing Solifenacin/Tamsulosin.
  • Open-House participation model with no individual contract negotiations.
Pokaż pełne podsumowanie

This is an Open-House supply arrangement for non-exclusive pharmaceutical rebate agreements for Solifenacin/Tamsulosin (ATC G04CA53) led by AOK PLUS. Any interested pharmaceutical company may join during the participation period if it meets and accepts the stated conditions. No individual negotiations or supply exclusivity apply. The contract term ends no later than 2028-02-29. Participation is handled electronically via DTVP project space, but the submission method is described as technically constrained and not fully consistent across the notice data.

Ryzyka

The notice says participation applications can be submitted electronically via DTVP, but also states that some portal i...

Demand is unknown and minimum purchase quantities are not guaranteed, so revenue volume is uncertain.

Analiza może być niepełna

Przeanalizowano tylko część dokumentacji. Pozostałe dokumenty mogą zawierać dodatkowe wymagania, certyfikaty lub dokumenty do złożenia.

Kluczowe wymagania

Technical

  • Applicant must be a pharmaceutical company within the meaning of the cited German pharmaceutical law provisions for the offered medicinal product.
  • The bidder must accept the participation conditions and the rebate agreement terms.

Eligibility

  • The bidder must submit the completed declaration of non-existence of exclusion grounds under §§ 123, 124 GWB.

Zamawiający

Lokalizacja

Erfurt, DEU

Profil zamawiającego

Otwórz profil

Identyfikator

DE256878834

Działalność

Health

Części (1)

LOT-0001

Open-house rebate agreement for Solifenacin/Tamsulosin

Non-exclusive supply contract for pharmaceutical rebate agreements concerning Solifenacin/Tamsulosin (ATC G04CA53). The lot is an Open-House model, so all interested pharmaceutical companies may participate if they satisfy the participation conditions. Place of performance is Germany, specifically Dresden in Saxony/Thuringia context as stated in the notice data.

SuppliesFrameworkEU fundedElectronic submission

Lokalizacja

Dresden, Germany

Czas trwania

Feb 2026 - Feb 2028

Kategoria

Pharmaceutical products

Termin

Deadline Feb 29, 2028

Szczegóły zamówienia

Data publikacji
22 Dec 2025
Języki
German

Metadane referencyjne

Podstawa prawna
32014L0024

Identyfikatory referencyjne

ID przetargu
856012-2025

Dokumenty (1)

Dokument zamówienia 1

Podobne przetargi

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3